SEARCH FOR LOCAL COVERAGE

REQUEST A REP

REQUEST SAMPLES

UBRELVY® WORKS DIFFERENTLY
THAN TRIPTANS^1-3

DURING A MIGRAINE ATTACK, CGRP IS RELEASED FROM ONE NEURON  AND TRAVELS TO THE NEXT, SENDING OUT A PAIN SIGNAL¹

UBRELVY UBRELVY

TRIPTANS TRIPTANS

UBRELVY works by blocking CGRP by binding to its receptor and providing migraine relief

UBRELVY directly blocks CGRP by binding to its receptor on the postsynaptic neuron, thereby blocking pain signaling.^2,3

The clinical significance is not known.

UBRELVY IS NOT KNOWN TO CONSTRICT BLOOD VESSELS

WHEN ACTING ON THE MIGRAINE DISEASE PATHWAY.⁴

The clinical significance of this mechanism of action is unknown. 
See Important Safety Information for Warnings and Precautions.

Triptans prevent CGRP from being released but do not stop already released CGRP

Triptans attach to serotonin receptors on presynaptic neurons. This prevents more CGRP from being released, but CGRP that has already been released continues to circulate—which could allow pain signaling to continue.² Triptans are known to cause vasoconstriction when acting on the migraine disease pathway.¹

The clinical significance of this mechanism of action is unknown.

EXPLORE EXPERT SPEAKER PROGRAMS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).
In patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

Hypertension (HTN): Development or worsening of pre-existing HTN has been reported following the use of CGRP antagonists, including UBRELVY. Some patients who developed new-onset HTN had risk factors. There were cases requiring initiation of HTN treatment and, in some cases, hospitalization. HTN may occur at any time but was most frequently reported within 7 days of initiation. The CGRP antagonist was discontinued in many of the cases. Monitor patients for new-onset or worsening of pre-existing HTN and consider whether discontinuation of UBRELVY is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s phenomenon (RP): Development, recurrence, or worsening of pre-existing RP has been reported following the use of CGRP antagonists, including UBRELVY. In cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms. UBRELVY should be discontinued if signs or symptoms of RP develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of RP should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-250101

References: 1. Durham PL. CGRP-receptor antagonists—a fresh approach to migraine therapy? N Engl J Med. 2004;350(71):1073-1075. 2. Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies-successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338-350. 3. UBRELVY [package insert]. North Chicago, IL: AbbVie Inc.; 2025. 4. American Headache Society. Consensus statement: The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1-18.

IMPORTANT SAFETY INFORMATION

Contraindications

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

Contraindications

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

UBRELVY is contraindicated:

With concomitant use of strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin).
In patients with a history of serious hypersensitivity to ubrogepant or any ingredient of the product.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Cases, including anaphylaxis, dyspnea, facial or throat edema, rash, urticaria, and pruritus, have been reported. Hypersensitivity reactions can occur minutes, hours, or days after administration. Most reactions were not serious, and some led to discontinuation. If a serious or severe reaction occurs, discontinue UBRELVY and institute appropriate therapy.

Hypertension (HTN): Development or worsening of pre-existing HTN has been reported following the use of CGRP antagonists, including UBRELVY. Some patients who developed new-onset HTN had risk factors. There were cases requiring initiation of HTN treatment and, in some cases, hospitalization. HTN may occur at any time but was most frequently reported within 7 days of initiation. The CGRP antagonist was discontinued in many of the cases. Monitor patients for new-onset or worsening of pre-existing HTN and consider whether discontinuation of UBRELVY is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s phenomenon (RP): Development, recurrence, or worsening of pre-existing RP has been reported following the use of CGRP antagonists, including UBRELVY. In cases with small molecule CGRP antagonists, symptom onset occurred a median of 1.5 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms. UBRELVY should be discontinued if signs or symptoms of RP develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of RP should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions were nausea (4% vs 2% placebo) and somnolence (3% vs 1% placebo).

DRUG INTERACTIONS

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure.
Dose modifications are recommended when using the following:
- Moderate or weak CYP3A4 inhibitors and inducers
- BCRP and/or P-gp only inhibitors

INDICATION

UBRELVY^® (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

Please see full Prescribing Information.

US-UBR-250101